This article contains content that is written like an advertisement. Please help improve it by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (June 2023) (Learn how and when to remove this template message)

ViiV Healthcare
Company typeJoint venture
IndustryPharmaceutical industry
Founded2009; 15 years ago (2009)
HeadquartersLondon, England, UK
Area served
Worldwide
Key people
Deborah Waterhouse (CEO)
ProductsPharmaceuticals
Owners
Number of employees
c. 1,100 (2023)
Websiteviivhealthcare.com

ViiV Healthcare (/ˈviːv/ VEEV) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS, with its global headquarters in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company.[1] In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi.[2] According to The Financial Times, the company’s co-ownership structure may change depending on the achievement of certain milestones.[1]

ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.[3]

ViiV Healthcare's global headquarters are in Brentford, Greater London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[4]

Products

The company markets 17 products:[5]

Treatment access programs

ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low- and middle-income countries, as well as all of Sub-Saharan Africa.[7]

The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.[7][8]

In March 2020, ViiV Healthcare announced the initiation of a study in partnership with University of South Carolina's Ryan White Program to determine the effectiveness of ride-sharing services in improving access to care for people living with HIV.[9]

See also

References

  1. ^ a b Jacks, Andrew "GSK and Pfizer to Merge HIV Portfolios Financial Times. 16 April 2010 (subscription required)
  2. ^ "Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio". viivhealthcare.com. Retrieved 7 March 2014.
  3. ^ "ViiV vows joint venture will help fight HIV". www.ft.com. Retrieved 3 November 2023.
  4. ^ "ViiV Healthcare Company Website. About Us — Locations" Archived 9 December 2010 at the Wayback Machine Accessed 13 October 2010
  5. ^ "Our HIV medicines". Retrieved 10 March 2022.
  6. ^ "Generic Rescriptor Availability". Drugs.com. Retrieved 10 March 2022.
  7. ^ a b "ViiV Healthcare Company Website. We Improve Access to Our Medicines" Accessed 12 January 2014
  8. ^ Reuters "Glaxo, Pfizer JV Opens HIV Pipeline to Generic Companies" Africa — the Good News. 19 July 2010
  9. ^ "ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV". Olean Times Herald. Retrieved 3 March 2020.
Categories